Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects

  • Qiangqiang Li
  • Konstantinos Dimopoulos
  • Chen Zhang
  • Yan Zhu
  • Qian Liu
  • Hong Gu
Original Article

Abstract

Inhaled prostacyclin analogue iloprost is currently utilized in adult patients with pulmonary arterial hypertension (PAH), but little information is available on its use in the pediatric population. This study evaluated the safety and acute haemodynamic effects of inhaled iloprost in children with PAH associated with congenital heart disease (CHD). Children with PAH–CHD who underwent cardiac catheterization and iloprost administration in our catheter laboratory between June 2007 and October 2015 were included. Iloprost was administered by atomization inhalation and changes in hemodynamic parameters were recorded. In total, 100 children with PAH–CHD were enrolled. Median age was 13 [1.5–18.0] years and 34% were male. A ventricular septal defect was present in 84%, a patent duct in 12%, a complete atrioventricular septal defect in 2%, and an isolated atrial septal defect in 2%. Pulmonary vascular resistance indexed (PVRI) was above 8 WU m2 in 96% and was above a third systemic (Rp/Rs > 0.33) in 97%. Iloprost was well tolerated in all patients. Following iloprost inhalation, mean pulmonary arterial pressure decreased from 78.4 ± 9.2 to 72.8 ± 10.8 mmHg (p < 0.01) and pulmonary-to-systemic blood flow ratio (Qp/Qs) increased from 1.12 ± 0.48 to 1.37 ± 0.63 (p < 0.01), with no change in cardiac index (Qs). PVRI decreased from 21.0 ± 9.0 to 16.9 ± 8.0 WU m2 (p < 0.01) following inhalation but 92% patients still had a PVRI > 8 WU m2 and 93% an Rp/Rs > 0.33. Acute inhalation of iloprost in children with PAH associated with CHD resulted in a significant improvement in hemodynamic parameters. Despite this, few patients achieve strict criteria of operability, underscoring the importance of early screening and timely repair of CHD.

Keywords

Catheterization Congenital heart defect Pulmonary arterial hypertension 

Notes

Compliance with Ethical Standards

Conflict of interest

Hong Gu, Qiangqiang Li, Chen Zhang, Yan Zhu, and Qian Liu have no conflict of interest. Konstantinos Dimopoulos has received unrestricted educational and research funds and has acted as a Consultant for Actelion, GSK, MSD, and Pfizer.

Ethical Approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Lang IM, Gaine SP (2015) Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev 24:630–641CrossRefPubMedGoogle Scholar
  2. 2.
    Sung KW, Jeon YB, Kim NY, Park KY, Park CH, Choi CH et al (2013) The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease. Cardiology 126:224–229CrossRefPubMedGoogle Scholar
  3. 3.
    Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ et al (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51:161–169CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kenny D, Hijazi ZM (2012) To inhale or to nebulize: treating the pulmonary vascular bed post-operatively in children with congenital heart disease. Cardiol J 19:335–336CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang DZ, Zhu XY, Meng J, Xue HM, Sheng XT, Han XM et al (2011) Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. Int J Cardiol 147:433–437CrossRefPubMedGoogle Scholar
  6. 6.
    Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B et al (2001) Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 103:544–548CrossRefPubMedGoogle Scholar
  7. 7.
    Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Aerosolized Iloprost Randomized Study Group.Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329CrossRefPubMedGoogle Scholar
  8. 8.
    Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P (2009) Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv 73:98–104CrossRefPubMedGoogle Scholar
  9. 9.
    Gorenflo M, Gu H, Xu Z (2010) Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology 116:10–17CrossRefPubMedGoogle Scholar
  10. 10.
    Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP test study group. Circulation 106:I76–I81PubMedGoogle Scholar
  11. 11.
    Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119CrossRefPubMedGoogle Scholar
  12. 12.
    Wilkinson JL (2001) Haemodynamic calculations in the catheter laboratory. Heart 85:113–120CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hallioglu O, Dilber E, Celiker A (2003) Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 92:1007–1009CrossRefPubMedGoogle Scholar
  14. 14.
    D’Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G, Mélot C, Russo MG, Naeije R, Calabrò R (2010) Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart 96:1475–1479CrossRefPubMedGoogle Scholar
  15. 15.
    Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, Gatzoulis MA (2010) Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121:20–25CrossRefPubMedGoogle Scholar
  16. 16.
    Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N (2014) Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 35(11):716–724CrossRefPubMedGoogle Scholar
  17. 17.
    Apitz C, Hansmann G, Schranz D (2016) Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease: expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension: the European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii23–ii29CrossRefPubMedGoogle Scholar
  18. 18.
    Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E (2010) Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG): ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31(23):2915–2957CrossRefPubMedGoogle Scholar
  19. 19.
    Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease); American Society of Echocardiography; Heart Rhythm Society; International Society for Adult Congenital Heart Disease; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons (2008) ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52(23):e143–e263CrossRefPubMedGoogle Scholar
  20. 20.
    Tissot C, Beghetti M (2009) Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 5:325–331PubMedPubMedCentralGoogle Scholar
  21. 21.
    Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O et al (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43:56S–61SCrossRefPubMedGoogle Scholar
  22. 22.
    Dimopoulos K, Wort SJ, Gatzoulis MA (2014) Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 35(11):691–700CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Qiangqiang Li
    • 1
  • Konstantinos Dimopoulos
    • 2
  • Chen Zhang
    • 1
  • Yan Zhu
    • 1
  • Qian Liu
    • 1
  • Hong Gu
    • 1
  1. 1.Department of Pediatric Cardiology, Beijing Anzhen HospitalCapital Medical UniversityBeijingChina
  2. 2.Adult Congenital Heart Centre and Centre for Pulmonary HypertensionRoyal Brompton Hospital and Imperial CollegeLondonUK

Personalised recommendations